Compare Medpace Holdings Inc (MEDP) vs VanEck Rare Earth/Strategic Metals (REMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs VanEck Rare Earth/Strategic Metals — how do they compare? Medpace Holdings Inc trades at $597.39 (market cap $16.90B), while VanEck Rare Earth/Strategic Metals trades at $77.3. The key difference: Medpace Holdings Inc is trading nearer its 52-week high, VanEck Rare Earth/Strategic Metals nearer its low. Which is the better fit depends on your goals.
| MEDP | REMX | |
|---|---|---|
Market Cap | $16.90B | — |
Sector | Technology | Sector/Thematic |
52-Week High | $620.59 | $109.53 |
52-Week Low | $393.42 | $56.60 |
Enterprise Value | $16.52B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.
MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.
REMX (VanEck Rare Earth and Strategic Metals ETF) trades at $77.03, down 1.81% with a bullish technical signal from moving averages but neutral oscillators. The ETF provides exposure to 38 global rare earth companies, though key financial ratios remain undisclosed. Recent news highlights U.S. efforts to secure critical minerals supply chains amid China's export controls, with Energy Fuels expanding domestic production capacity.
Outlook hinges on geopolitical rare earth dynamics and U.S. supply chain independence initiatives. Risks include high volatility (~50% annualized) and China concentration. Analyst sentiment is mixed due to thematic reliance on policy shifts and commodity cycles, warranting caution for conservative investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About VanEck Rare Earth/Strategic Metals
REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.
Read more on REMX →
